Lamdin et al. brindan evidencia adicional respecto a los beneficios de salud asociados con estas intervenciones para reducción de daños. Más información, en inglés, está disponible abajo. 

By Barrot H. Lambdin PhD, Peter J. Davidson PhD, Erica N. Browne MS, Leslie W. Suen MD, Lynn D. Wenger MSW, MPH & Alex H. Kral PhD / Journal of General Internal Medicine 



Safe consumption sites (SCS) are an evidence-based intervention to prevent drug use–related harm. In late 2014, an organisation in an undisclosed location in the USA opened an unsanctioned SCS.


To evaluate whether use of the unsanctioned SCS affected medical outcomes.


A prospective cohort study.


Neighbourhoods surrounding the SCS.


People who injected drugs were recruited and interviewed at baseline and 6 and 12 months from 2018 to 2020.


People using the SCS could bring pre-obtained drugs to consume via injection, which were monitored by trained staff with naloxone.

Main Measures

Any overdose, number of non-fatal overdoses, skin and soft tissue infections, emergency department utilisation, number of emergency department visits, hospitalisation and number of nights spent in hospital.

Key Results

A total of 494 participants enrolled in the study; 59 (12%) used the SCS at least once. We used propensity score weighting to analyse the association between SCS utilisation and measures. People using the SCS were 27% (95% CI: 12–46%) less likely to visit the emergency department, had 54% (95% CI: 33–71%) fewer emergency department visits, were 32% (95% CI: 4–57%) less likely to be hospitalised, and spent 50% (95% CI: 1–85%) fewer nights in hospital. Though not significant, people using the SCS had a lower likelihood of overdosing and slightly higher likelihood of skin and soft tissue infections.


Our findings support the use of SCS in the USA to reduce the growing burden of acute care service utilisation related to injection drug use.